Opportunities
Search

Buyer: Coöperatieve Vereniging Midwaste Milieu U.A. | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-21

Buyer: SIC DJI | Notice type: cn-social | Procedure: open | Contract: services | Deadline: 2026-10-21

Buyer: MINARM/SCA/PFC-RBT | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-21

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged.Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions.Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Clinical Research Award (CRA) supports clinical research that evaluates disease-specific factors and interventions. Research is intended to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Research addressing any and all types of arthritis is encouraged.Applications must address one of two FY26 ATRP CRA Focus Areas: Prevention and Early Diagnosis, or Treatment and Mitigation of Disease Progression/Burden.Distinctive Features: The FY26 ATRP CRA offers funding for two research levels. It is the responsibility of the applicant to select the level that aligns with the scope of the proposed research.• Research Level 1: Applications proposing clinical research or early-phase/pilot clinical trials, to include new or emerging research that is not ready for a full-scale randomized controlled clinical trial.• Research Level 2: Applications proposing a full-scale clinical trial.Applications should include a community collaborator (e.g., patient/care partner, community-based organization consultant) who will provide advice and consultation during study design and throughout study planning and implementation. The ATRP encourages a community collaborator for Research Level 1 applications and requires a community collaborator for Research Level 2 applications.Preliminary and/or published data are required.

Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Idea Development Award (IDA) is to support conceptually innovative research that could lead to impactful discoveries or significant advancements that will accelerate progress toward reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or the quality of life. Applications should propose research that is conceptually innovative, introduces a new concept or question, challenges existing paradigms, approaches issues from a new perspective, or exhibits other uniquely creative qualities; and should not merely be a next logical step or an incremental advance on published data or ongoing research. Distinctive Features: A Career Development Option is available to eligible early-career investigators who propose to conduct impactful mechanism-relevant research under the mentorship of an experienced tick-borne disease researcher(s). Applications submitted under the IDA – Career Development Option (IDA-CDO) will be reviewed using separate, career development-specific evaluation criteria by a separate, dedicated peer review panel; and are subject to a lower cost limit than those submitted under the standard IDA.https://cdmrp.health.mil/pubs/press/2026/tbdrppreann

Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings.  https://cdmrp.health.mil/pubs/press/2026/tbdrppreann

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for Autistic individuals. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Idea Development Award Areas of Interest or provide justification that the proposed research addresses a critical problem, question, or need in autism.Partnering Principal Investigator (PI) Option: The Partnering PI Option is structured so that two investigators, each of whom will be designated as a PI, will work synergistically on a single project. The results of this partnering project should significantly advance the research beyond what would be possible through individual efforts.

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Clinical Trial Award Areas of Interest.Partnering Principal Investigator (PI) Option for Early-Career Investigator: The FY26 Clinical Trial Award mechanism is offering a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in autism clinical trial research.FY26 Clinical Trial Award submissions are required to include community collaborations to optimize research impact. Research teams are therefore required to establish and utilize effective and equitable collaborations and partnerships with community members to maximize the translational and impact potential of the proposed research. Applications to the FY26 ARP Clinical Trial Award are expected to name at least one community partner (e.g., A...

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Career Development Award supports early-career, independent investigators and/or the transition of established investigators from other research fields to conduct innovative, high-impact ideas or early-phase, proof-of-principle clinical trials with the potential to have a major impact on autism.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Career Development Award Areas of Interest or provide justification that the proposed research addresses a critical problem, question, or need in autism.FY26 Career Development Award submissions with a pilot clinical trial component are required to include community collaborations to optimize research impact. Applications are expected to name at least one community partner (e.g., an Autistic individual or caregiver, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

NIMH seeks applications for pilot research to adapt, optimize, and test behavioral interventions that address common sleep problems in adolescents and young adults with or at risk for a mental health disorder. This notice of funding opportunity (NOFO) supports pilot clinical trials designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach in real world settings. Applications should aim to conduct a preliminary test of the intervention's impact on sleep and mental health outcomes, as well as an examination of the mechanisms that underlie the intervention's effectiveness, and to obtain preliminary data needed as a prerequisite for larger-scale effectiveness trials. In addition, interdisciplinary, collaborative teams of investigators from the fields of mental health, sleep medicine, developmental science, clinical trials research methods, behavioral economics, implementation science, data science, and human computer interaction are encouraged.

Buyer: OSAKIDETZA - Servicio Vasco de Salud - Hospital Universitario Cruces (Impulsora) | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-22

Buyer: ΓΝΑ ΣΙΣΜΑΝΟΓΛΕΙΟ - Α.ΦΛΕΜΙΓΚ | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-22

Buyer: Gemeente Woerden | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-10-22

Buyer: Stichting Carmelcollege | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-22

Buyer: VZW Onderwijsgroep Zusters der Christelijke Scholen Midden-Kempen | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-22

Buyer: VZW Onderwijsgroep Zusters der Christelijke Scholen Midden-Kempen | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-22

Buyer: Trenitalia S.p.A | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-23

Buyer: Stichting Regionaal Opleidingen Centrum Aventus | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-23

Buyer: Helsingin kaupunki, kaupunkiympäristön toimiala, asuntotuotanto | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-10-23

Buyer: Helsingin kaupunki, kaupunkiympäristön toimiala, asuntotuotanto | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-10-23

Buyer: COMUNE DI IMPERIA | Notice type: cn-standard | Contract: services | Deadline: 2026-10-23

Buyer: Zdravotnická záchranná služba Jihočeského kraje | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-23

Buyer: Zakład Usług Komunikacyjnych „ROKBUS” Sp. z o.o. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-23

Buyer: Trafikverket Myndighet | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-23